Mazyar Shadman: Novel BTK Inhibitors and DOACs A Multicenter Study of Bleeding Risk
Mazyar Shadman, Deputy Chief Medical Officer at Fred Hutch, shared Brenda Castillo’s post on LinkedIn, adding:
”Excited for this large, multicenter collaboration evaluating the bleeding risk associated with concomitant use of novel BTK inhibitors and direct oral anticoagulants (DOACs).
Led by Brenda Castillo, MD a superstar senior fellow at Fred Hutch.”
Brenda Castillo, Hematology Oncology Fellow Physician at University of Washington, shared a post on LinkedIn:
”Excited to share that our multicenter cohort study evaluating major bleeding in patients with CLL treated with BTK inhibitors and DOACs has been selected for presentation at this year’s ASH Annual Meeting!
Grateful to our collaborators and looking forward to sharing our findings.”
Stay updated with Hemostasis Today.
-
Nov 7, 2026, 15:54Hassan Raza: Beyond the 100 Minus Age Rule in Bone Marrow Cellularity
-
Nov 7, 2026, 15:42Andrew Zapfel։ Advancing Sickle Cell Disease Care Through Training, Advocacy and Collaboration
-
Nov 7, 2026, 15:34Salih Ehsan: Iron Deficiency Beyond Conventional Ferritin Cutoffs
-
Nov 7, 2026, 15:21Shamee Shastry: Improving the Reliability and Reproducibility of the Monocyte Monolayer Assay
-
Nov 7, 2026, 14:39AI-Assisted Donor Screening and Transfusion Decision Support: A Prospective Multicentre Evaluation
-
Nov 7, 2026, 14:26Qiong Tang: Changing Perspectives on Iron Deficiency and Supplementation
-
Nov 7, 2026, 14:21Nathan Connell: Bringing VWD Education Across Borders to Improve Patient Care
-
Nov 7, 2026, 14:02David McIntosh: Thalassaemia Care Needs More Than Breakthrough Therapies
-
Nov 7, 2026, 14:00Farzin Beygui: SOLOTAVI Tests Aspirin Discontinuation After TAVI